Idea or Concept – Page 3

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

2 months ago talkbio0Tagged Biological Factors, CNS disorder, Praxis Precision Medicines, Pricing, public entity

Praxis Precision Medicines; public offering; $525 million; stock offering; share offering; pricing; biopharmaceutical; central nervous system disorders

BioCryst Snaps Up Fellow Angioedema Player Astria for $700M

2 months ago talkbio0Tagged Acquisition, Angioedemas, Hereditary, Astria, BioCryst, Cash, Drug Industry, navenibart, Rare Diseases

BioCryst; Astria Therapeutics; acquisition; hereditary angioedema (HAE); navenibart; rare disease; pharmaceutical industry; cash and stock deal; Jill Milne; $700 million

Bicycle Health Grows Leadership Team to Expand Access for Justice-Involved Populations

2 months ago talkbio0Tagged Andy Thomas, Bicycle Health, Business Development, Criminal Justice, executive team, Leadership, Opioid Use Disorder, Steve Tomlin, virtual care

Bicycle Health; Leadership team; Executive team; Steve Tomlin; Business development; Criminal justice; Opioid use disorder; Virtual care; Manu Kuppalli; Andy Thomas

AI is Transforming Drug Safety—But Governance Sets Essential Guardrails

2 months ago talkbio0Tagged Adverse reaction to drug, AI guardrails, Artificial Intelligence, Bias (Epidemiology), Data Integrity, drug safety, Jeavons syndrome, patient safety, Pharmacovigilance, regulatory governance, United States Food and Drug Administration

artificial intelligence; drug safety; pharmacovigilance; adverse drug events; regulatory governance; FDA; EMEA; AI guardrails; data integrity; bias; patient safety

Recent Trends in Biomarker Testing for NSCLC: Maximizing Real-World Survival

2 months ago talkbio0Tagged ALK gene, biomarker testing, Epidermal Growth Factor Receptor, Liquid Biopsy, next-generation sequencing, Non-Small Cell Lung Carcinoma, Overall Survival, PD-L1, Precision Medicine, Real-world

NSCLC; biomarker testing; overall survival; PD-L1; EGFR; ALK; next-generation sequencing; liquid biopsy; precision medicine; real-world data

Sanofi Expands $35 Insulin Program to All U.S. Patients Nationwide

3 months ago talkbio0Tagged Affordability, Diabetes, Insulin, Insurance, Medicare, monthly, Programs - Publication Format, sanofi, United States

Sanofi; Insulin; $35 monthly program; Insulins Valyou Savings Program; diabetes; insurance coverage; Medicare; affordability; United States

Kai Beckmann Appointed as Successor to Merck KGaA CEO Belén Garijo, Effective May 2026

3 months ago talkbio0Tagged Belén Garijo, business career, CEO, Corporate, Electronic, Executive Board, governance, Health Care Sector, Kai Beckmann, Leadership Transition, Merck KGaA, strategic transformation, succession

Merck KGaA; Kai Beckmann; Belén Garijo; CEO Succession; Electronics Business; Executive Board; Leadership Transition; Healthcare sector; Corporate governance; Strategic transformation

CDC Advisors Shift COVID-19 Vaccine Guidance to Individual Decision-Making

3 months ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), Consultation, COVID19 (disease), individual choice, Provider, Recommendation, Vaccines

CDC; COVID-19 vaccine; vaccine recommendation; individual choice; ACIP; provider consultation

Sanofi’s MS Drug Tolebrutinib Faces FDA Delay Amid Extended Review

3 months ago talkbio0Tagged Breakthrough Therapy, Bruton 's tyrosine kinase inhibitor, Deferred, GEMINI trial, HERCULES trial, Multiple Sclerosis, NDA, nrSPMS, PERSEUS trial, regulatory review, sanofi, Tolebrutinib, United States Food and Drug Administration

Sanofi; tolebrutinib; FDA delay; multiple sclerosis; nrSPMS; Bruton’s tyrosine kinase inhibitor; breakthrough therapy; HERCULES trial; GEMINI trial; PERSEUS trial; NDA; regulatory review

Langers Team Launch $77.5M Fund to Invest at Intersection of Technology and Biology

3 months ago talkbio0Tagged biology (field), Capital, Fund I, Geographic Intersection, Investments, Michael Langer, Robert Langer, Technology, venture capital

T.Rx Capital; Robert Langer; Michael Langer; intersection of technology and biology; biotech investments; venture capital; Fund I